Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of 2.07 billion. The enterprise value is 4.00 billion.
| Market Cap | 2.07B |
| Enterprise Value | 4.00B |
Important Dates
The last earnings date was Friday, January 31, 2025.
| Earnings Date | Jan 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 180.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.57 |
| EV / Sales | 1.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -39.12 |
Financial Position
The company has a current ratio of 0.67, with a Debt / Equity ratio of 2.25.
| Current Ratio | 0.67 |
| Quick Ratio | 0.37 |
| Debt / Equity | 2.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | -23.30 |
| Interest Coverage | -29.53 |
Financial Efficiency
Return on equity (ROE) is -69.06% and return on invested capital (ROIC) is -21.62%.
| Return on Equity (ROE) | -69.06% |
| Return on Assets (ROA) | -14.65% |
| Return on Invested Capital (ROIC) | -21.62% |
| Return on Capital Employed (ROCE) | -63.54% |
| Revenue Per Employee | 476,033 |
| Profits Per Employee | -224,843 |
| Employee Count | 4,980 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +120.34% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +120.34% |
| 50-Day Moving Average | 3.39 |
| 200-Day Moving Average | 11.21 |
| Relative Strength Index (RSI) | 66.88 |
| Average Volume (20 Days) | 5,296 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of 2.37 billion and -1.12 billion in losses. Loss per share was -2.82.
| Revenue | 2.37B |
| Gross Profit | 1.43B |
| Operating Income | -1.43B |
| Pretax Income | -1.23B |
| Net Income | -1.12B |
| EBITDA | -1.24B |
| EBIT | -1.43B |
| Loss Per Share | -2.82 |
Balance Sheet
The company has 543.14 million in cash and 2.38 billion in debt, giving a net cash position of -1.84 billion.
| Cash & Cash Equivalents | 543.14M |
| Total Debt | 2.38B |
| Net Cash | -1.84B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.06B |
| Book Value Per Share | 2.66 |
| Working Capital | -1.05B |
Cash Flow
In the last 12 months, operating cash flow was -36.06 million and capital expenditures -66.17 million, giving a free cash flow of -102.23 million.
| Operating Cash Flow | -36.06M |
| Capital Expenditures | -66.17M |
| Free Cash Flow | -102.23M |
| FCF Per Share | n/a |
Margins
Gross margin is 60.52%, with operating and profit margins of -60.14% and -47.23%.
| Gross Margin | 60.52% |
| Operating Margin | -60.14% |
| Pretax Margin | -52.02% |
| Profit Margin | -47.23% |
| EBITDA Margin | -52.29% |
| EBIT Margin | -60.14% |
| FCF Margin | n/a |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.00% |
| Earnings Yield | -54.21% |
| FCF Yield | -4.95% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of -0.43. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.43 |
| Piotroski F-Score | n/a |